- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
House Passes MaineCare Expansion, Gov Wants Change
AUGUSTA, Maine (AP) — The Maine House on Monday approved a bill to expand the state's Medicaid program to include roughly 70,000 more people, a key component of the national Affordable Care Act.
Representatives voted 89-51 for the bill Monday, adding changes aimed at mitigating worries of Republicans who've opposed expansion in past votes. The amended version says the state can opt out of the Medicaid expansion if the federal government doesn't match its share of the cost as promised. The bill faces a Senate vote as early as Tuesday.
Last week, the federal Health and Human Services Department confirmed it will pay 100 percent of the cost of expansion for the three calendar years starting in 2014, reaching 90 percent in 2020. But minority Republicans have remained concerned about potential expense to the state despite government promises, saying it will cost $400 million in Maine taxpayers' money in the seven years after the first three-year full-coverage period.
Read the full story here: http://buswk.co/15ImyaG
Source: Bloomberg Businessweek
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
